Pfizer Inc. (NYSE:PFE) Shares Sold by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 67,980 shares of the biopharmaceutical company’s stock after selling 7,326 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Pfizer were worth $1,804,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Hanson & Doremus Investment Management lifted its position in Pfizer by 1.0% during the 4th quarter. Hanson & Doremus Investment Management now owns 139,121 shares of the biopharmaceutical company’s stock worth $3,691,000 after acquiring an additional 1,408 shares in the last quarter. Allen Capital Group LLC lifted its holdings in Pfizer by 10.2% in the fourth quarter. Allen Capital Group LLC now owns 125,582 shares of the biopharmaceutical company’s stock worth $3,332,000 after acquiring an additional 11,661 shares during the last quarter. Strategic Blueprint LLC boosted its position in Pfizer by 2.0% during the 4th quarter. Strategic Blueprint LLC now owns 47,169 shares of the biopharmaceutical company’s stock valued at $1,251,000 after purchasing an additional 942 shares during the period. Hantz Financial Services Inc. increased its holdings in shares of Pfizer by 34.5% in the 4th quarter. Hantz Financial Services Inc. now owns 514,184 shares of the biopharmaceutical company’s stock worth $13,641,000 after acquiring an additional 131,760 shares during the period. Finally, Foster Victor Wealth Advisors LLC raised its stake in Pfizer by 24.9% during the 4th quarter. Foster Victor Wealth Advisors LLC now owns 564,035 shares of the biopharmaceutical company’s stock valued at $14,834,000 after acquiring an additional 112,616 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PFE shares. Bank of America restated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Finally, UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

Shares of NYSE PFE opened at $26.65 on Thursday. The firm has a 50 day moving average of $26.18 and a 200 day moving average of $27.91. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm has a market capitalization of $151.00 billion, a price-to-earnings ratio of 36.01, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period last year, the company posted ($0.17) earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.46%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.